Our data indicate that liver iron stores were not altered by TMPRSS6 siRNA treatment but splenic iron stores increased, consistent with this therapy redistributing iron stores rather than inducing systemic iron depletion, a feature that could protect patients from symptomatic iron deficiency. Here, TMPRSS6 is linked to Iron deficiency anemia.